Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank14
5Y CAGR-4.5%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-4.5%/yr
Long-term compound
Percentile
P14
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 3.40% |
| 2024 | 14.78% |
| 2023 | 19.09% |
| 2022 | -12.96% |
| 2021 | 66.77% |
| 2020 | 4.27% |
| 2019 | 23.87% |
| 2018 | 6.93% |
| 2017 | 26.43% |
| 2016 | 5.17% |